These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33180463)

  • 1. COVID-19 in the Developing World: Is the Immune Response to α-Gal an Overlooked Factor Mitigating the Severity of Infection?
    Hodžić A; de la Fuente J; Cabezas-Cruz A
    ACS Infect Dis; 2020 Dec; 6(12):3104-3108. PubMed ID: 33180463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B careful: Humoral responses and COVID-19 severity.
    Fanous H; Guerrero-Pena A; Pillai A
    Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity to glycan α-Gal and possibilities for the control of COVID-19.
    la Fuente J; Gortázar C; Cabezas-Cruz A
    Immunotherapy; 2021 Feb; 13(3):185-188. PubMed ID: 33307805
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis of SARS-CoV-2 infection in the setting of the cytokine release syndrome.
    Azar MM; Shin JJ; Kang I; Landry M
    Expert Rev Mol Diagn; 2020 Nov; 20(11):1087-1097. PubMed ID: 32990479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19: Significance of antibodies.
    Assadiasl S; Fatahi Y; Zavvar M; Nicknam MH
    Hum Antibodies; 2020; 28(4):287-297. PubMed ID: 32986664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Bacterial and Fungal Human Respiratory Microbiota in COVID-19 Patients.
    Soltani S; Zakeri A; Zandi M; Kesheh MM; Tabibzadeh A; Dastranj M; Faramarzi S; Didehdar M; Hafezi H; Hosseini P; Farahani A
    Biomed Res Int; 2021; 2021():6670798. PubMed ID: 33681368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
    Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waning Antibody Responses in Asymptomatic and Symptomatic SARS-CoV-2 Infection.
    Choe PG; Kang CK; Suh HJ; Jung J; Song KH; Bang JH; Kim ES; Kim HB; Park SW; Kim NJ; Park WB; Oh MD
    Emerg Infect Dis; 2021 Jan; 27(1):327-9. PubMed ID: 33050983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 and ABO blood groups.
    Ryabkova VA; Churilov LP; Shoenfeld Y
    Isr Med Assoc J; 2021 Mar; 23(3):140-142. PubMed ID: 33734622
    [No Abstract]   [Full Text] [Related]  

  • 10. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
    Bouayad A
    Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antibody response to the glycan α-Gal correlates with COVID-19 disease symptoms.
    Urra JM; Ferreras-Colino E; Contreras M; Cabrera CM; Fernández de Mera IG; Villar M; Cabezas-Cruz A; Gortázar C; de la Fuente J
    J Med Virol; 2021 Apr; 93(4):2065-2075. PubMed ID: 33009829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are Seroprevalence Estimates for Severe Acute Respiratory Syndrome Coronavirus 2 Biased?
    Takahashi S; Greenhouse B; Rodríguez-Barraquer I
    J Infect Dis; 2020 Nov; 222(11):1772-1775. PubMed ID: 32856712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics of viral load and antibody response in relation to COVID-19 severity.
    Wang Y; Zhang L; Sang L; Ye F; Ruan S; Zhong B; Song T; Alshukairi AN; Chen R; Zhang Z; Gan M; Zhu A; Huang Y; Luo L; Mok CKP; Al Gethamy MM; Tan H; Li Z; Huang X; Li F; Sun J; Zhang Y; Wen L; Li Y; Chen Z; Zhuang Z; Zhuo J; Chen C; Kuang L; Wang J; Lv H; Jiang Y; Li M; Lin Y; Deng Y; Tang L; Liang J; Huang J; Perlman S; Zhong N; Zhao J; Malik Peiris JS; Li Y; Zhao J
    J Clin Invest; 2020 Oct; 130(10):5235-5244. PubMed ID: 32634129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing SARS-CoV-2.
    Poeschla E
    Elife; 2020 Dec; 9():. PubMed ID: 33320086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid in vitro assays for screening neutralizing antibodies and antivirals against SARS-CoV-2.
    Park JG; Oladunni FS; Chiem K; Ye C; Pipenbrink M; Moran T; Walter MR; Kobie J; Martinez-Sobrido L
    J Virol Methods; 2021 Jan; 287():113995. PubMed ID: 33068703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 pandemic: insights into molecular mechanisms leading to sex-based differences in patient outcomes.
    Kumar A; Narayan RK; Kulandhasamy M; Prasoon P; Kumari C; Kumar S; Pareek V; Sesham K; Shekhawat PS; Kant K; Kumar S
    Expert Rev Mol Med; 2021 Aug; 23():e7. PubMed ID: 34340720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Immunity against SARS-CoV-2: walking to the vaccination].
    Rodríguez Hernández C; Sanz Moreno L
    Rev Esp Quimioter; 2020 Dec; 33(6):392-398. PubMed ID: 32935536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The microbiome in atopic patients and potential modifications in the context of the severe acute respiratory syndrome coronavirus 2 pandemic.
    Lee E; Hong SJ
    Curr Opin Allergy Clin Immunol; 2021 Jun; 21(3):245-251. PubMed ID: 33769313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.
    Li K; Huang B; Wu M; Zhong A; Li L; Cai Y; Wang Z; Wu L; Zhu M; Li J; Wang Z; Wu W; Li W; Bosco B; Gan Z; Qiao Q; Wu J; Wang Q; Wang S; Xia X
    Nat Commun; 2020 Nov; 11(1):6044. PubMed ID: 33247152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.